NewAmsterdam Pharma (NASDAQ:NAMSW) Short Interest Update

NewAmsterdam Pharma (NASDAQ:NAMSW) was the recipient of a significant decline in short interest during the month of June. As of June 15th, there was short interest totaling 42 shares, a decline of 40.8% from the May 31st total of 71 shares. Based on an average daily trading volume, of 1,378 shares, the days-to-cover ratio is presently 0.0 days.

Institutional Investors Weigh In On NewAmsterdam Pharma

A hedge fund recently bought a new position in NewAmsterdam Pharma stock. Aristeia Capital L.L.C. acquired a new stake in NewAmsterdam Pharma (NASDAQ:NAMSW) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 15,708 shares of the company’s stock, valued at approximately $397,000.

NewAmsterdam Pharma Stock Performance

NAMSW stock traded up $2.19 during midday trading on Wednesday, reaching $23.55. The stock had a trading volume of 1,000 shares, compared to its average volume of 1,862. The firm has a fifty day simple moving average of $22.13 and a two-hundred day simple moving average of $22.22. NewAmsterdam Pharma has a 52-week low of $8.41 and a 52-week high of $30.45.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.

The company’s lead program is an oral glucagon?like peptide?1 (GLP-1) receptor agonist currently in early clinical trials.